|Table of Contents|

Semi-quantitative analysis of salivary gland scintigraphy for predictive evaluation and dynamic monitoring of impaired salivary gland function after 131I treatment of DTC patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 06
Page:
1043-1047
Research Field:
Publishing date:

Info

Title:
Semi-quantitative analysis of salivary gland scintigraphy for predictive evaluation and dynamic monitoring of impaired salivary gland function after 131I treatment of DTC patients
Author(s):
LI Zeyang1; LI Hesong1; ZHAO Xiaoyi2; XI Yongchang2; SONG Huimin2; TANG Man2; GE Jianing2
1.Chengde Medical University，Hebei Chengde 067000,China；2.Baoding No.1 Central Hospital,Hebei Baoding 071000,China.
Keywords:
differentiated thyroid cancer; radioactive sialadenitis; 131I treatment; salivary gland imaging; semi-quantitative analysis
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2024.06.010
Abstract:
Objective:To evaluate the salivary gland function in patients with differentiated thyroid carcinoma (DTC) before and after 131I therapy using semi-quantitative analysis of radionuclide imaging.This study aimed to explore the predictive value of semi-quantitative parameters derived from salivary gland scintigraphy (SGS) in assessing salivary gland damage and develop effective indicators for early prediction of salivary gland dysfunction.Methods:A retrospective study was conducted on 72 patients with DTC who underwent postoperative 131I therapy and 40 patients who did not receive 131I therapy after surgery in Baoding No.1 Central Hospital from 2020 to 2022.Semi-quantitative parameters,including the uptake rate at 15 minutes (UR15‰),concentrate index (CI),maximum secretion ratio (MSR%),and time interval from stimulation to minimum count (Tmin),were measured using SGS before and after treatment.The Oral Dryness-Severity Scale (ODSS) was used to assess xerostomia symptoms.The relationship between semi-quantitative parameters and salivary gland damage was analyzed,and effective indicators for predicting salivary gland dysfunction were identified.Results:There were no significant differences in bilateral parotid CI,bilateral submandibular UR15‰,CI,and Tmin in the 72 DTC patients who underwent 131I therapy (P＞0.05).However,significant differences were observed in bilateral parotid UR15%,MSR%,Tmin,and bilateral submandibular MSR%(P＜0.05).Negative correlations were found between ΔMSR%(r=-0.58),ΔTmin (r=-0.42) in bilateral parotid glands,ΔMSR%(r=-0.45),ΔTmin(r=-0.33) in bilateral submandibular glands,and salivary gland damage.Conclusion:Some patients with DTC who underwent 131I therapy may experience salivary gland dysfunction.Impairment in salivary gland excretion precedes impairment in uptake function,and decreased MSR% and Tmin may indicate salivary gland excretion dysfunction,while CI and UR15‰ may suggest uptake function impairment.

References:

［1］中华医学会核医学分会.131I治疗分化型甲状腺癌指南(2014版)［J］.中华核医学与分子影像杂志,2014,34(4):264-278. Chinese Society of Nuclear Medicine,Chinese Medical Association.Guidelines for the 131I therapy of differentiated thyroid cancer (2014 edition)［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2014,34(4):264-278.
［2］AZIZMOHAMMADI Z,TABEI F,SHAFIEI B.A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroidremnant ablation treatment ［J］.Hell J Nucl Med,2013,16(2):103-106.
［3］ DARROUZET E,LINDENTHAL S,MARCELLIN D,et al.The sodium/iodide symporter:state of the art of its molecular characterization［J］.Biochim Biophys Acta,2014,1838(1 Pt B):244-253.
［4］ KLEIN HESSELINK EN,LINKS TP.Radioiodine treatment and thyroid hormone suppression therapy for differentiated thyroid carcinoma:adverse effects support the trend toward less aggressive treatment for low-risk patients［J］.Eur Thyroid J,2015,4(2):82-92.
［5］ LAKSHMANAN A,SCARBERRY D,SHEN DH,et al.Modulation of sodium iodide symporter in thyroid cancer［J］.Horm Cancer,2014,5(6):363-373.
［6］BUCHHOLZER S,FAURE F,TCHEREMISSINOFF L,et al.Novel multidisciplinary salivary gland society (MSGS) questionnaire:An international consensus［J］.Laryngoscope,2022,132(2):322-331.
［7］ 周科,贾志云.核素动态显像对131I治疗分化型甲状腺癌患者唾液腺损伤程度的评价［J］.解放军预防医学杂志,2019,37(01):83-85,99. ZHOU K,JIA ZY.Evaluation of salivary gland damage in patients with differentiated thyroid cancer treated with 131I therapy using dynamic nuclear imaging ［J］.Journal of Military Preventive Medicine,2019,37(01):83-85,99.
［8］ 王丽萍,方雷,张辉,等.分化型甲状腺癌患者术后不同剂量131I治疗对唾液腺功能影响的系统评价［J］.甘肃科学学报,2020,32(03):56-60. WANG LP,FANG L,ZHANG H,et al.Systematic evaluation of the impact of different doses of postoperative 131I therapy on salivary gland function in patients with differentiated thyroid cancer ［J］.Journal of Gansu Sciences,2020,32(03):56-60.
［9］ 杨文定,邹劲涛,覃卫华,等.分化型甲状腺癌术后患者首次131I“清甲”治疗后对唾液腺功能的影响［J］.中国临床医学影像杂志,2018,29(05):313-315. YANG WD,ZOU JT,QIN WH,et al.Impact of initial "ablation" therapy with 131I on salivary gland function in patients with differentiated thyroid cancer after surgery ［J］.Chinese Journal of Clinical Medical Imaging,2018,29(05):313-315.
［10］UPADHYAYA A,ZHOU P,MENG Z,et al.Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer:a randomized-controlled trial［J］.Nucl Med Commun,2017,38(11):891-903.
［11］ANJOS DA,ETCHEBEHERE EC,SANTOS AO,et al.Normal values of ［99mTc］pertechnetate uptake and excretion fraction by major salivary glands［J］.Nucl Med Commun,2006,27(4):395-403.
［12］ 杨阳.131I治疗对分化型甲状腺癌患者唾液腺功能和骨代谢影响［J］.生物医学工程与临床,2019,23(02):156-160. YANG Y.Effects of 131I therapy on salivary gland function and bone metabolism in patients with differentiated thyroid cancer ［J］.Biomedical Engineering and Clinical,2019,23(02):156-160..
［13］JELLEMA AP,SLOTMAN BJ,DOORNAERT P,et al.Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer［J］.Int J Radiat Oncol Biol Phys,2007,69(3):751-760.
［14］裴蔚,廖海,苏丹柯.磁共振功能成像评价放射性涎腺损伤的研究进展［J］.临床放射学杂志,2021,40(03):610-614. PEI W,LIAO H,SU DK.Research progress on magnetic resonance functional imaging for the evaluation of radiation-induced salivary gland injury［J］.Journal of Clinical Radiology,2021,40(03):610-614.
［15］KITA T,YOKOYAMA K,HIGUCHI T,et al.Multifactorial analysis on the short-term side effects occurring within 96 hour after radioiodine-131 therapy for differentiated thyroid carcinoma ［J］.Annals of Nuclear Medicine,2004,18(4):345-349.
［16］ALEXANDER C,BADER JB,SCHAEFER A,et al.Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma［J］.Journal of Nuclear Medicine,1998,39(9):1551-1554.
［17］凌小冬,刘海珍.放射性核素131I治疗甲状腺癌的近期疗效与安全性［J］.临床合理用药杂志,2022,15(23):91-94. LING XD,LIU HZ.Recent efficacy and safety of radioactive 131I therapy for thyroid cancer［J］.Journal of Rational Pharmacotherapy,2022,15(23):91-94.
［18］VISSINK A,MITCHELL JB,BAUM BJ,et al.Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients:successes and barriers［J］.Int J Radiat Oncol Biol Phys,2010,78(4):983-991.
［19］JENSEN SB,PEDERSEN AM,VISSINK A,et al.A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies:prevalence,severity and impact on quality of life［J］.Support Care Cancer,2010,18(8):1039-1060.
［20］LV X,YIN L,WU W,et al.Quantitative scintigraphy evaluated the relationship between 131I therapy and salivary glands function in DTC patients:A retrospective analysis［J］.J Healthc Eng,2022,2022:7640405.
［21］YANG L,MA J,LEI P,et al.Advances in antioxidant applications for combating 131I side effects in thyroid cancer treatment［J］.Toxics,2023,11(6):529.
［22］BAUDIN C,BRESSAND A,BUFFET C,et al.Dysfunction of the salivary and lacrimal glands after radioiodine therapy for thyroid cancer:Results of the START study after 6-months of follow-up［J］.Thyroid,2023,33(9):1100-1109.

Memo

Memo:
河北省保定市科技计划（编号：2241ZF043）
Last Update: 1900-01-01